2 news items
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GLUE
9 May 24
period in 2023. Collaboration revenue represents revenue recorded under the Roche License and Collaboration agreement. Research
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GLUE
14 Mar 24
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $27.1 million, compared to $24.9
- Prev
- 1
- Next